Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$428 Mln
Revenue (TTM)
$120 Mln
Net Profit (TTM)
$0 Mln
ROE
0.3 %
ROCE
-- %
P/E Ratio
8.9
P/B Ratio
2
Industry P/E
28.15
EV/EBITDA
4.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$0.7
Face value
--
Shares outstanding
71,441,104
CFO
$171.63 Mln
EBITDA
$662.89 Mln
Net Profit
$261.49 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
SIGA Technologies (SIGA)
| 0.9 | 1.3 | 1.3 | -20.3 | -6.4 | 1.3 | 11.7 |
|
BSE Sensex*
| 3.8 | 3.4 | 6.9 | 9.7 | 15.4 | 21.9 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
SIGA Technologies (SIGA)
| 7.3 | -23.9 | -2.1 | 3.4 | 52.4 | -39.6 | 62.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
SIGA Technologies (SIGA)
|
6.1 | 427.9 | 120.3 | 48.5 | 48.3 | 25.2 | 8.9 | 2.0 |
| 20.2 | 4,700.7 | 459.4 | 206.8 | 25.6 | 68.3 | 23.4 | 12.6 | |
| 108.3 | 5,294.4 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 99.5 | |
| 59.4 | 11,366.6 | 2,937.8 | 523.9 | 23.2 | 9.3 | 22 | 2.0 | |
| 33.7 | 6,425.6 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 74.8 | 7,961.9 | 685.5 | 132.9 | 15.6 | 20.1 | 65.3 | 11.7 | |
| 13.2 | 6,416.7 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.2 | 1.0 | |
| 63.8 | 12,254.9 | 4,413.2 | 21.3 | 7.2 | 0.6 | 316.6 | 3.3 | |
| 88.9 | 4,402.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 20.8 | 2.4 | |
| 8.8 | 10,375.3 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The... company was incorporated in 1995 and is headquartered in New York, New York. Read more
Executive VP, CFO & Secretary
Mr. Daniel J. Luckshire
Executive VP & Chief Scientific Officer
Dr. Dennis E. Hruby Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of SIGA Technologies Inc (SIGA) stood at $ 275 Mln as on 31-Mar-25
The share price of SIGA Technologies Inc (SIGA) is $6.07 (NASDAQ) as of 19-May-2025 16:00 EDT. SIGA Technologies Inc (SIGA) has given a return of -6.37% in the last 3 years.
SIGA Technologies Inc (SIGA) has a market capitalisation of $ 428 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of SIGA Technologies Inc (SIGA) is 1.98 times as on 16-May-2025, a 57% discount to its peers’ median range of 4.61 times.
The P/E ratio of SIGA Technologies Inc (SIGA) is 8.94 times as on 16-May-2025, a 68% discount to its peers’ median range of 28.15 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the SIGA Technologies Inc (SIGA) and enter the required number of quantities and click on buy to purchase the shares of SIGA Technologies Inc (SIGA).
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
The CEO & director of Mr. Daniel J. Luckshire. is SIGA Technologies Inc (SIGA), and CFO & Sr. VP is Dr. Dennis E. Hruby Ph.D..
There is no promoter pledging in SIGA Technologies Inc (SIGA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,178
|
|
|
1,126
|
|
|
988
|
|
|
751
|
|
|
647
|
|
|
639
|
|
|
510
|
|
|
475
|
|
|
422
|
| SIGA Technologies Inc. (SIGA) | Ratios |
|---|---|
|
Return on equity(%)
|
25.17
|
|
Operating margin(%)
|
48.34
|
|
Net Margin(%)
|
40.33
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of SIGA Technologies Inc (SIGA) was $0 Mln.
$0.08
(
